Poster today from Mayo Clinic experience shows no survival difference between the pts they enrolled on ruxo over the years and patients contemporaneously enrolled.
Not much info on the poster concerning whether they attempted to case match, but the OS curves are atop each other.
I'm assuming the survival data I previously tweeted about comes from INCY directly.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.